Needham & Company LLC Forecasts Strong Price Appreciation for Evolent Health (NYSE:EVH) Stock

Key Points

• Needham raised its price target on Evolent Health to $6 from $5 and maintained a Buy rating, implying 31.15% upside from the prior close. Analysts’ consensus rating is Moderate Buy, with a $6.04 average target.
• Evolent reported quarterly EPS of $0.06, in line with estimates, while revenue rose 51.3% year over year to $725.37 million—slightly below forecasts. The company issued FY 2026 revenue guidance of $2.6 billion to $2.7 billion, with the midpoint above consensus.
• Profitability remains a concern: Evolent reported a negative net margin of 24.08%, despite its strong revenue growth.

Evolent Health (NYSE:EVH - Get Free Report) had its price target lifted by equities researchers at Needham & Company LLC from $5.00 to $6.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has a "buy" rating on the technology company's stock. Needham & Company LLC's price target points to a potential upside of 31.15% from the stock's previous close.

EVH has been the topic of a number of other reports. JPMorgan Chase & Co. boosted their target price on Evolent Health from $5.00 to $6.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 18th. Truist Financial cut their price target on Evolent Health from $7.00 to $6.00 and set a "hold" rating for the company in a report on Wednesday, August 12th. Canaccord Genuity Group cut their price target on Evolent Health from $7.00 to $6.00 and set a "buy" rating for the company in a report on Monday, August 10th. TD Cowen lifted their price objective on Evolent Health from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Monday, August 17th. Finally, Weiss Ratings cut Evolent Health from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, October 16th. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $6.04.

Evolent Health Price Performance

EVH traded down $0.23 during trading on Thursday, hitting $4.58. 3,491,526 shares of the company traded hands, compared to its average volume of 2,841,592. The company has a market cap of $517.25 million, a PE ratio of -1.00 and a beta of 1.03. The stock's 50-day simple moving average is $4.17 and its two-hundred day simple moving average is $3.88. Evolent Health has a 1 year low of $2.10 and a 1 year high of $6.34. The company has a current ratio of 1.24, a quick ratio of 1.24 and a debt-to-equity ratio of 2.52.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The technology company reported $0.06 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.06. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 4.27%. The company had revenue of $725.37 million for the quarter, compared to the consensus estimate of $727.06 million. During the same period in the previous year, the firm posted $0.05 EPS. Evolent Health's revenue for the quarter was up 51.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Evolent Health will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Evolent Health news, President Daniel Mccarthy sold 65,892 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $5.00, for a total transaction of $329,460.00. Following the sale, the president directly owned 655,133 shares of the company's stock, valued at $3,275,665. The trade was a 9.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.48% of the company's stock.

Institutional Investors Weigh In On Evolent Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vise Technologies Inc. lifted its stake in shares of Evolent Health by 76.5% during the 3rd quarter. Vise Technologies Inc. now owns 30,215 shares of the technology company's stock worth $105,000 after acquiring an additional 13,096 shares during the last quarter. State of Wyoming increased its stake in Evolent Health by 37.3% in the third quarter. State of Wyoming now owns 113,074 shares of the technology company's stock worth $395,000 after purchasing an additional 30,720 shares during the period. Tempus Wealth Planning LLC lifted its position in shares of Evolent Health by 20.2% during the third quarter. Tempus Wealth Planning LLC now owns 100,774 shares of the technology company's stock worth $352,000 after purchasing an additional 16,969 shares during the last quarter. Congress Asset Management Co. lifted its position in shares of Evolent Health by 20.3% during the third quarter. Congress Asset Management Co. now owns 275,158 shares of the technology company's stock worth $960,000 after purchasing an additional 46,466 shares during the last quarter. Finally, Sequoia Financial Advisors LLC bought a new position in shares of Evolent Health in the second quarter worth about $78,000.

Trending Headlines about Evolent Health

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Evolent issued FY 2026 revenue guidance of $2.6 billion to $2.7 billion. The midpoint is above analysts’ $2.6 billion consensus, and the high end suggests potential upside to expectations.
• Positive Sentiment: Q3 earnings were $0.06 per share, matching estimates and up from $0.05 a year earlier. Revenue rose 51.3% year over year to $725.37 million. CEO Seth Blackley said customers are renewing agreements and, in many cases, expanding their work with Evolent. Evolent Announces Third Quarter 2026 Results
• Negative Sentiment: Quarterly revenue was slightly below analysts’ $727.06 million estimate. The company also reported a negative net margin of 24.08%, highlighting that profitability remains a concern despite strong revenue growth.

Evolent Health Company Profile

Evolent Health, Inc NYSE: EVH is a healthcare services and technology company that helps health plans and healthcare providers transition to value-based care. Its platform is designed to support the management of clinical programs, improve patient outcomes and coordinate care while helping customers manage healthcare costs.

The company provides specialty and total-cost-of-care solutions across areas such as cardiology, oncology, musculoskeletal care, radiology and other complex conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.